Dynamic test with recombinant interferon-alpha-2b

effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease

C. Natoli, C. Garufi, N. Tinari, M. D'Egidio, G. Lesti, L. A. Gaspari, R. Visini, S. Iacobelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We have previously shown that a short course of recombinant interferon-alpha-2b (rIFN-alpha-2b) (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed 1 month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31 %) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients.

Original languageEnglish
Pages (from-to)564-567
Number of pages4
JournalBritish Journal of Cancer
Volume67
Issue number3
Publication statusPublished - Mar 1993

Fingerprint

interferon alfa-2b
Neoplasm Antigens
Neoplasms
Serum
Breast Neoplasms
Time and Motion Studies
alpha-Fetoproteins
Ovarian Neoplasms
Colonic Neoplasms
Population
Early Diagnosis
Colorectal Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Natoli, C., Garufi, C., Tinari, N., D'Egidio, M., Lesti, G., Gaspari, L. A., ... Iacobelli, S. (1993). Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. British Journal of Cancer, 67(3), 564-567.

Dynamic test with recombinant interferon-alpha-2b : effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. / Natoli, C.; Garufi, C.; Tinari, N.; D'Egidio, M.; Lesti, G.; Gaspari, L. A.; Visini, R.; Iacobelli, S.

In: British Journal of Cancer, Vol. 67, No. 3, 03.1993, p. 564-567.

Research output: Contribution to journalArticle

Natoli, C, Garufi, C, Tinari, N, D'Egidio, M, Lesti, G, Gaspari, LA, Visini, R & Iacobelli, S 1993, 'Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease', British Journal of Cancer, vol. 67, no. 3, pp. 564-567.
Natoli, C. ; Garufi, C. ; Tinari, N. ; D'Egidio, M. ; Lesti, G. ; Gaspari, L. A. ; Visini, R. ; Iacobelli, S. / Dynamic test with recombinant interferon-alpha-2b : effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. In: British Journal of Cancer. 1993 ; Vol. 67, No. 3. pp. 564-567.
@article{c58a72a135ce4592b0a08010bb44d9a4,
title = "Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease",
abstract = "We have previously shown that a short course of recombinant interferon-alpha-2b (rIFN-alpha-2b) (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed 1 month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31 {\%}) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45{\%}) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients.",
author = "C. Natoli and C. Garufi and N. Tinari and M. D'Egidio and G. Lesti and Gaspari, {L. A.} and R. Visini and S. Iacobelli",
year = "1993",
month = "3",
language = "English",
volume = "67",
pages = "564--567",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Dynamic test with recombinant interferon-alpha-2b

T2 - effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease

AU - Natoli, C.

AU - Garufi, C.

AU - Tinari, N.

AU - D'Egidio, M.

AU - Lesti, G.

AU - Gaspari, L. A.

AU - Visini, R.

AU - Iacobelli, S.

PY - 1993/3

Y1 - 1993/3

N2 - We have previously shown that a short course of recombinant interferon-alpha-2b (rIFN-alpha-2b) (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed 1 month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31 %) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients.

AB - We have previously shown that a short course of recombinant interferon-alpha-2b (rIFN-alpha-2b) (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed 1 month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31 %) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0027447248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027447248&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 564

EP - 567

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -